ACE2 rupture force
27 single-molecule force spectroscopy studies (2020–2026), 2 with a public dataset.
Reported forces
| Observable | Value | Technique | Year | Study | Source sentence |
|---|---|---|---|---|---|
| Unfolding force | 40 pN | AFM | 2022 | A tethered ligand assay to probe SARS-CoV-2:ACE2 interactions. | This initial peak is followed by a trident-shaped, three-peak pattern at around 40 pN. |
| Rupture force | 1,500 pN | AFM | 2022 | A tethered ligand assay to probe SARS-CoV-2:ACE2 interactions. | The final ClfA:Fgɣ rupture at >1,500 pN is not shown, for clarity. |
| Unbinding force | 26 pN | AFM | 2022 | A tethered ligand assay to probe SARS-CoV-2:ACE2 interactions. | an initial (leftmost) peak typically at lower forces around 26 pN for the SARS-CoV-1 fusion construct and about twice as high forces for the SARS-CoV-2 fusion construct (around 57 pN; Fig. 2 A, Inset) |
| Unbinding force | 57 pN | AFM | 2022 | A tethered ligand assay to probe SARS-CoV-2:ACE2 interactions. | an initial (leftmost) peak typically at lower forces around 26 pN for the SARS-CoV-1 fusion construct and about twice as high forces for the SARS-CoV-2 fusion construct (around 57 pN; Fig. 2 A, Inset) |
| Contour length increment | 53 nm | AFM | 2022 | A tethered ligand assay to probe SARS-CoV-2:ACE2 interactions. | The contour length increments of the first peaks (53 and 66 nm for the short and long linkers, respectively), are, however, larger than what is expected from interface opening only |
| Contour length increment | 66 nm | AFM | 2022 | A tethered ligand assay to probe SARS-CoV-2:ACE2 interactions. | The contour length increments of the first peaks (53 and 66 nm for the short and long linkers, respectively), are, however, larger than what is expected from interface opening only |
Values as reported in each paper (auto-extracted from abstracts and AI-reviewed full texts); loading rates, constructs and buffers differ between studies, so compare with care.
Summary by observable
About this system
Essential counter-regulatory carboxypeptidase of the renin-angiotensin hormone system that is a critical regulator of blood volume, systemic vascular resistance, and thus cardiovascular homeostasis. Converts angiotensin I to angiotensin 1-9, a nine-amino acid peptide with anti-hypertrophic effects in cardiomyocytes, and angiotensin II to angiotensin 1-7, which then acts as a beneficial vasodilator and anti-proliferation agent, counterbalancing the actions of the vasoconstrictor angiotensin II. Also removes the C-terminal residue from three other vasoactive peptides, neurotensin, kinetensin, and des-Arg bradykinin, but is not active on bradykinin. Also cleaves other biological peptides, such as apelins (apelin-13, [Pyr1]apelin-13, apelin-17, apelin-36), casomorphins (beta-casomorphin-7, neocasomorphin) and dynorphin A with high efficiency. In addition, ACE2 C-terminus is homologous to collectrin and is responsible for the trafficking of the neutral amino acid transporter SL6A19 to the plasma membrane of gut epithelial cells via direct interaction, regulating its expression on the cell surface and its catalytic activity
From UniProt Q9BYF1 · CC BY 4.0
Angiotensin-converting enzyme 2 (ACE2) is an enzyme that can be found either attached to the membrane of cells (mACE2) in the intestines, kidney, testis, gallbladder, and heart or in a soluble form (sACE2). Both membrane bound and soluble ACE2 are integral parts of the renin–angiotensin–aldosterone system (RAAS) that exists to keep the body's blood pressure in check. mACE2 is cleaved by the enzyme ADAM17 in a process regulated by substrate presentation. ADAM17 cleavage releases the extracellular domain creating soluble ACE2 (sACE2). ACE2 enzyme activity opposes the classical arm of the RAAS by lowering blood pressure through catalyzing the hydrolysis of angiotensin II into angiotensin (1–7). Angiotensin (1-7) in turns binds to MasR receptors creating localized vasodilation and hence decreasing blood pressure. This decrease in blood pressure makes the entire process a promising drug targe
From Wikipedia, Angiotensin-converting enzyme 2 · CC BY-SA 4.0
Techniques
AFM force spectroscopy (20), Magnetic tweezers (4), Force spectroscopy (2), Optical tweezers (1)
Related
Studies
- 2025 From Attraction to Repulsion: Omicron-Driven Rewiring of Nanobody Interfaces on the SARS-CoV-2 RBD
- 2022 A tethered ligand assay to probe SARS-CoV-2:ACE2 interactions.
- 2026 Beyond ACE2: unveiling the receptor-mediated endocytic dynamic mechanism of SARS-CoV-2 at the single-particle level.
- 2026 Force-Activated Slip-Catch-Slip Bonds Stabilize Virus Interactions
- 2026 Force-regulated catch bonds and fusion peptide exposure drive coronavirus entry
- 2026 Heparin Modulates SARS-CoV-2 Spike-Platelet Factor 4 Interactions through Concentration-Dependent Interface Remodeling.
- 2026 Single molecule force spectroscopy for evaluating inhibitors of SARS-CoV-2 variants of concern.
- 2026 Switching Spike Plasticity Shapes ACE2 Engagement Across SARS-CoV-2 Variants.
- 2025 Direct measurement of SARS-CoV-2 spike RBD binding to integrin αvβ6 by single-molecule force spectroscopy.
- 2025 Modulation of SARS-CoV-2 spike binding to ACE2 through conformational selection.
- 2025 Molecular Insights into the Interaction between CD147 and the SARS-CoV‑2 Spike Protein.
- 2024 Single-Molecule Investigation of the Binding Interface Stability of SARS-CoV-2 Variants with ACE2.
- 2024 Single-molecule force stability of the SARS-CoV-2-ACE2 interface in variants-of-concern.
- 2024 Unveiling the Dynamic Mechanism of SARS-CoV-2 Entry Host Cells at the Single-Particle Level.
- 2024 Variant-specific interactions at the plasma membrane: Heparan sulfate’s impact on SARS-CoV-2 binding kinetics
- 2023 S373P Mutation Stabilizes the Receptor-Binding Domain of the Spike Protein in Omicron and Promotes Binding.
- 2022 Pathogen-Host Adhesion between SARS-CoV-2 Spike Proteins from Different Variants and Human ACE2 Probed at Single-Molecule and Single-Cell Levels
- 2022 Pathogen-host adhesion between SARS-CoV-2 spike proteins from different variants and human ACE2 studied at single-molecule and single-cell levels.
- 2022 S373P Mutation Stabilizes the Receptor-binding Domain of Spike Protein in Omicron and Promotes Binding
- 2022 Supported Natural Membranes on Microspheres for Protein-Protein Interaction Studies.
- 2021 A Tethered Ligand Assay to Probe SARS-CoV-2:ACE2 Interactions
- 2021 A molecularly engineered, broad-spectrum anti-coronavirus lectin inhibits SARS-CoV-2 and MERS-CoV infection in vivo
- 2021 Biomechanical characterization of SARS-CoV-2 spike RBD and human ACE2 protein-protein interaction.
- 2021 Endothelial glycocalyx shields the interaction of SARS-CoV-2 spike protein with ACE2 receptors.
- 2021 N501Y mutation of spike protein in SARS-CoV-2 strengthens its binding to receptor ACE2.
- 2020 A Tethered Ligand Assay to Probe the SARS-CoV-2 ACE2 Interaction under Constant Force
- 2020 Biomechanical Characterization of SARS-CoV-2 Spike RBD and Human ACE2 Protein-Protein Interaction